跳至主要内容
临床试验/NCT03786549
NCT03786549招募中不适用

Impact of a Pediatric-adult Care Transition Program on the Health Status of Patients With Sickle Cell Disease - A Randomized Controlled Trial

Hospices Civils de Lyon8 个研究点 分布在 1 个国家目标入组 196 人开始时间: 2019年1月16日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
196
试验地点
8
主要终点
Incidence of sickle cell related severe complications leading to hospitalization

研究概览

简要总结

Background The pediatric-adult care transition is a risk-disrupting time for patients with chronic disease. This care transition takes place during adolescence; a period of psychological upheavals and adaptations of family roles. During this period, medication adherence is non-optimal and absenteeism at medical appointments is high.

Sickle cell disease (SCD) is the first genetic disease detected in France. It is chronic disease characterized by frequent painful vaso-occlusive crises (VOC) requiring emergency hospitalization when they are severe. Other serious complications are acute chest syndromes (ACS) and stroke.

In order to improve the health status of teenagers with sickle cell disease, it is necessary to anticipate this care transition and to involve the pediatric and adult sectors. The biopsychosocial health approach and the Social-Ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) describe a care transition integrating bioclinical and psychosocial factors such as integration of the patient's family, education on disease and therapeutics, psychological management of pain and medico-social orientation.

The pediatric-adult transition program proposed is based on this biopsychosocial approach. It aims to improve the health status of adolescents with SCD, their quality of life and the use of health care service.

Objective of the study To assess the impact of a pediatric-adult transition program on the incidence of sickle-cell-related complications leading to hospitalization on 24-months after transfer to the adult sector.

The evaluation focuses on severe complications leading to hospitalization, such as VOC, ACS, and stroke.

Study design Multicenter Open-label individual Randomized Controlled Trial Population : Patients aged at least 16 years old with sickle cell disease, and their parents (or legal representatives Number of subject : 196 patients (98 patients by arm) The study will last 24 months Expected results For patients and families Better health and quality of life for patients is expected, including better use of medical care after the transition program. It is also expected a better experience of the pediatric-adult care transition and indirectly a better experience of intrafamilial relations.

For health professionals This project is expected to provide solutions to improve the pediatric-adult care transition of patients with chronic disease. Indeed, the methodological quality of the study will make it possible to evaluate the efficiency of the proposed program, to possibly adapt it and test it to other chronic diseases presenting the same care transition problematic.

In terms of public health SCD mainly affects populations of sub-Saharan origin, with low visibility and high social vulnerability. By focusing on this population, this project will reduce the social inequalities in health, experienced by patients with SCD and their families.

By improving the health, quality of life and care of patients with SCD, this project is expected to decrease the cost of the pediatric-adult care transition period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
16 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • For patients :
  • Age: 16-17 years,
  • With major sickle cell syndrome, defined by hemoglobinopathy of homozygosity SS, or double heterozygosity SC or Sβ-thalassemia,
  • Benefiting from social insurance of the type "Affection of long duration" (ALD).
  • For family members :
  • Included children's parents or legal representatives,
  • Accepting to participate in the study and having signed the informed consent.

排除标准

  • Presenting a cognitive or psychiatric disorder known and major that may hinder interventions or evaluation, the judgment of the investigator, and / or having a family history with this type of disorders,
  • Cured of SCD by an allograft of hematopoietic stem cells.

结局指标

主要结局

Incidence of sickle cell related severe complications leading to hospitalization

时间窗: Within 24 months after transfer to the adult sector

Number of hospital admission or emergency visit in the index hospital

次要结局

  • Medication Intake Survey-Asthma (MIS-A) questionnaire score(At inclusion)
  • HLS-EU-Q16 score(within 24 months after transfer to the adult sector)
  • Frequency of emergency visits in the index hospital(Within 12 and 24 months after transfer to the adult sector)
  • Medication Rating Scale (MARS) questionnaire score(At inclusion)
  • MIS-A questionnaire score(within 24 months after transfer to the adult sector)
  • Self efficacy specific instrument - sickle cell disease (SCD-SES) questionnaire score(At inclusion)
  • MARS questionnaire score(within 24 months after transfer to the adult sector)
  • Number of days absent at school(within 24 months after transfer to the adult sector)
  • EUropean Health Literacy questionnaire (HLS-EU-Q16) score(At inclusion)
  • Patient activation measure-13 items questionnaire score(within 24 months after transfer to the adult sector)
  • number of pediatric-adult transition program sessions performed(Up to 4 years)
  • World Health Organization Quality of Life (WHOQOL) questionnaire score(At inclusion)
  • Disease knowledge(within 24 months after transfer to the adult sector)
  • SCD-SES questionnaire score(within 24 months after transfer to the adult sector)
  • WHOQOL questionnaire score(within 24 months after transfer to the adult sector)
  • Transition readiness assessment questionnaire (TRAQ) questionnaire score(At inclusion)
  • type of pediatric-adult transition program sessions performed(Up to 4 years)
  • TRAQ questionnaire score(within 24 months after transfer to the adult sector)
  • cost effectiveness ratio(Up to 4 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验